Dr. Paul Jedlicka, Children’s Hospital of Colorado - $5k​

The Jedlicka laboratory has identified a molecular pathway in Ewing Sarcoma that promotes tumor growth and tumor metastasis. Excitingly, since this pathway involves an enzyme (a protein called KDM3A, a type of “epigenetic modifier”) allowing the Jedlicka laboratory to work hard to understand exactly how KDM3A promotes Ewing Sarcoma cell growth and metastasis, to determine how best to inhibit its action. These funds may also be used for so-called pharmacokinetic/ pharmacodynamic studies to determine optimal drug dosing in our animal tumor model.